Hyperuricemia
📧 Sign up to get email alerts when something new happens for Hyperuricemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2024-05-08Clinical Trial Update: Distribution of Immune Cells and Their Subtypes in Peripheral Blood of Gout
Clinical trial update examining immune cell distribution and subtypes in peripheral blood of individuals with gout, including gout flare, in…
-
FDA approval · 2024-04-03FDA Approved: ALLOPURINOL — Supplemental Application (Actavis Pharma, Inc.)
FDA approved a supplemental application for Allopurinol from Actavis Pharma, Inc., authorizing changes to the product’s labeling.
-
FDA label_change · 2024-03-08FDA Approved: ALLOPURINOL — Supplemental Application (Harman Finochem Limited)
FDA approved a supplemental application for Allopurinol, approving changes to the labeling for Harman Finochem Limited's generic Allopurinol…
-
FDA approval · 2024-02-16FDA Approved: ALLOPURINOL — Supplemental Application (Par Health USA, LLC)
The FDA approved a supplemental application for Allopurinol submitted by Par Health USA, LLC.
-
FDA approval · 2024-02-05FDA Approved: ALLOPURINOL — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
FDA approved a supplemental application for allopurinol from Heritage Pharmaceuticals (d/b/a Avet Pharmaceuticals) under ANDA204467. The app…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-02-05FDA Approved: ALLOPURINOL — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for ALLOPURINOL (Allopurinol) submitted by Zydus Lifesciences Limited, authorizing changes to the ap…
-
FDA approval · 2024-01-29FDA Approved: ALLOPURINOL — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for Allopurinol from Sun Pharmaceutical Industries, Inc., indicating an approved update to the drug'…
-
FDA label_change · 2024-01-29FDA Approved: ALLOPURINOL — Supplemental Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved a supplemental application for Allopurinol submitted by Unichem Pharmaceuticals (USA), Inc., resulting in changes to the produc…
-
CLINICAL_TRIALS trial_result · 2023-12-14Clinical Trial Update: Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia [Phase 4]
Phase 4 trial reporting that orlistat reduces uric acid in overweight/obese patients with hyperuricemia.
-
FDA approval · 2023-11-29FDA Approved: FEBUXOSTAT — Supplemental Application (Tris Pharma Inc)
The FDA approved a supplemental application for febuxostat from Tris Pharma Inc, enabling a generic version of the gout medication.
-
FDA approval · 2023-11-28FDA Approved: FEBUXOSTAT — Supplemental Application (Solco Healthcare US LLC)
FDA approved a supplemental application for febuxostat from Solco Healthcare US LLC, authorizing changes to the approved product.
-
FDA approval · 2023-11-20FDA Approved: PROBENECID — Supplemental Application (Rising Pharma Holdings, Inc.)
The FDA approved a supplemental application for Probenecid filed by Rising Pharma Holdings, Inc., typically related to changes in labeling o…
-
FDA approval · 2023-11-20FDA Approved: PROBENECID — Original Application (Rising Pharma Holdings, Inc.)
The FDA approved Rising Pharma Holdings' original application for a generic probenecid product. Probenecid is a uricosuric agent used to tre…
-
FDA approval · 2023-10-25FDA Approved: FEBUXOSTAT — Original Application (Aurobindo Pharma Limited)
FDA approved the original application for febuxostat submitted by Aurobindo Pharma Limited, authorizing marketing of a generic febuxostat pr…
-
FDA approval · 2023-09-28FDA Approved: FEBUXOSTAT — Original Application (Macleods Pharmaceuticals Limited)
FDA approved an original Abbreviated New Drug Application (ANDA) for febuxostat tablets 40 mg and 80 mg by Macleods Pharmaceuticals Limited.…
-
FDA approval · 2023-09-19FDA Approved: FEBUXOSTAT — Supplemental Application (Zydus Lifesciences Limited)
FDA approved a supplemental application for febuxostat filed by Zydus Lifesciences Limited under the ANDA.
-
FDA approval · 2023-09-18FDA Approved: ALLOPURINOL — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for allopurinol submitted by Mylan Pharmaceuticals Inc. (ANDA 018659).
-
FDA approval · 2023-08-15FDA Approved: FEBUXOSTAT — Supplemental Application (Novadoz Pharmaceuticals LLC)
FDA approved a supplemental application for febuxostat from Novadoz Pharmaceuticals LLC.
-
FDA approval · 2023-08-15FDA Approved: FEBUXOSTAT — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for febuxostat submitted by Ascend Laboratories, LLC.
-
FDA approval · 2023-08-09FDA Approved: FEBUXOSTAT — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for Febuxostat submitted by Sun Pharmaceutical Industries, Inc.
-
FDA approval · 2023-08-09FDA Approved: FEBUXOSTAT — Supplemental Application (DR REDDY'S LABORATORIES LIMITED)
The FDA approved a supplemental application for febuxostat submitted by Dr. Reddy's Laboratories Limited.
-
FDA approval · 2023-08-03FDA Approved: ALLOPURINOL — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' allopurinol via Original Application (ANDA 217748), granting a generic version of the drug.
-
FDA approval · 2023-07-26FDA Approved: FEBUXOSTAT — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for febuxostat from Alembic Pharmaceuticals Limited. The action indicates regulatory approval for a …
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201) [Phase 2]
Phase 2 trial update of ALLN-346 (engineered urate oxidase) in hyperuricemic subjects has completed enrollment and status.
-
CLINICAL_TRIALS trial_result · 2023-06-22Clinical Trial Update: Efficacy and Safety of Kui-Yuan Chewable Tablets in Patients With Hyperuricemia [Phase 4]
Phase 4 clinical trial update evaluating efficacy and safety of Kui-Yuan Chewable Tablets in hyperuricemia patients.